- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01733030
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls. (DCS)
The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.
PROJECT SUMMARY:
PTSD is a debilitating psychiatric condition precipitated by exposure to extreme, or life threatening, trauma with an estimated lifetime prevalence between 8% and 9% in U.S. adults. One core symptom of PTSD is intense psychological distress in the presence of stimuli that "resemble" one or more aspects of the trauma experience (DSM-IV). This phenomenon referred to as stimulus generalization has received surprisingly little empirical testing in the context of clinical anxiety in general, and PTSD more specifically. The current proposal represents the first effort to study the neurobiology and pharmacology of this PTSD-relevant learning phenomenon across those with and without PTSD. The objective of this particular proposal is to apply fMRI and pharmacologic methods to: 1) identify brain mechanisms associated with generalization of conditioned fear and 2) examine the pharmacologic modifiability of levels of generalization using a partial agonist at the NMDA receptor complex (D-cycloserine) shown to increase discrimination of CS+ (danger cue) and CS- (safety cue) in animal studies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthy adults between the ages of 18-55.
Exclusion Criteria:
- Current or past Axis I psychiatric diagnosis as determined by self report
- Current substance dependence or meet criteria for the six month period preceding testing.
Participants will be excluded if they have current or past medical illnesses, which place the participant at risk or confound the results of the study including:
A) Past history of hypersensitivity to Seromycin B) Current or past epileptic disorders C) Current depression D) Current anxiety disorders E) Current or past psychotic disorders F) Current or past renal disease G) Excessive or concurrent use of alcohol
a) Subjects who are unable to abstain from alcohol for 12 hours prior to testing and 2 days following testing will be excluded
- Current use of psychoactive medications or medications that alter central-nervous-system function
- Females who are pregnant or currently breast-feeding
- Any metallic implants or objects above the knee, tattoos about the knee, or oral braces.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
250 mg Seromycin
Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
|
250 mg versus 500 mg versus placebo effects on conditioned fear generalization
Other Names:
|
500 mg Seromycin
Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
|
250 mg versus 500 mg versus placebo effects on conditioned fear generalization
Other Names:
|
Placebo
Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
fMRI (BOLD) responses
Time Frame: 1/1/13-6/1/14
|
fMRI (BOLD) responses
|
1/1/13-6/1/14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Behavioral assessments of perceived danger
Time Frame: up to three years
|
Behavioral assessments of perceived danger
|
up to three years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shmuel Lissek, PhD, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Anti-Bacterial Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Anti-Infective Agents, Urinary
- Renal Agents
- Cycloserine
Other Study ID Numbers
- MH080130
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Traumatic Stress Syndrome
-
University of Colorado, DenverNational Endowment for the Arts, United StatesRecruitingDepression, Anxiety | Post-Traumatic Stress Disorder | Burn-Out SyndromeUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingFibrosis | Post-traumatic Stress Disorder | Post-COVID Syndrome | SequelaeFrance
-
Bambino Gesù Children's Hospital IRCCSMinistry of Health, ItalyRecruitingDepression | Anxiety | Post Traumatic Stress Disorder | Narrative Medicine | Post Intensive Care SyndromeItaly
-
University Hospital, BordeauxHospices Civils de Lyon; Centre Hospitalier de Cadillac, FranceCompletedPost-Traumatic Stress Disorder | Post-Concussion SymptomsFrance
-
Paul G. Harch, M.D.Semper Fi Fund; Marine Corps-Law Enforcement Foundation; Coalition to Support... and other collaboratorsCompletedTBI (Traumatic Brain Injury) | Post Traumatic Stress Disorder | Post Concussion Syndrome | Chronic Post Traumatic Stress DisorderUnited States
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
US Department of Veterans AffairsCompletedGulf War Syndrome | Chronic Fatigue Syndrome | Post-Traumatic Stress DisorderUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
University of ZurichCompletedPost Traumatic Stress Disorder (PTSD) | Complex Post-Traumatic Stress Disorder (CPTSD)Switzerland
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
Clinical Trials on Seromycin
-
Yale UniversityVA Connecticut Healthcare SystemCompleted
-
Mclean HospitalUniversity of MinnesotaCompletedSchizophrenia | Bipolar Disorder
-
Hadassah Medical OrganizationUnknownTraumatic Brain InjuryIsrael
-
Indiana UniversityNational Institute of Mental Health (NIMH); National Alliance for Research... and other collaboratorsCompleted
-
Massachusetts General HospitalCompletedBody Dysmorphic DisorderUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)Completed
-
Massachusetts General HospitalHartford HospitalCompletedObsessive-Compulsive Disorder
-
Indiana UniversityUnited States Department of DefenseCompletedAutistic Disorder | Asperger's Disorder | Pervasive Developmental Disorder NOSUnited States